Compare CRDF & PMTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRDF | PMTS |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.7M | 152.4M |
| IPO Year | 2012 | 2015 |
| Metric | CRDF | PMTS |
|---|---|---|
| Price | $1.80 | $13.56 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.63 | ★ $27.67 |
| AVG Volume (30 Days) | ★ 689.6K | 74.3K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ 1.25 |
| Revenue | $365,993.00 | ★ $312,189,000.00 |
| Revenue This Year | N/A | $9.95 |
| Revenue Next Year | N/A | $10.02 |
| P/E Ratio | ★ N/A | $11.22 |
| Revenue Growth | ★ 49.61 | 12.27 |
| 52 Week Low | $1.48 | $10.81 |
| 52 Week High | $4.56 | $30.51 |
| Indicator | CRDF | PMTS |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 45.20 |
| Support Level | $1.51 | $12.26 |
| Resistance Level | $2.05 | $13.86 |
| Average True Range (ATR) | 0.12 | 1.13 |
| MACD | 0.00 | -0.15 |
| Stochastic Oscillator | 16.92 | 22.60 |
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.